<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carglumic acid: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carglumic acid: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carglumic acid: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="15624" href="/d/html/15624.html" rel="external">see "Carglumic acid: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="17067" href="/d/html/17067.html" rel="external">see "Carglumic acid: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10107689"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Carbaglu</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871159"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Carbaglu</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F10109473"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Metabolic Alkalosis Agent;</li>
<li>
                        Urea Cycle Disorder (UCD) Treatment Agent</li></ul></div>
<div class="block doa drugH1Div" id="F10228991"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f3782e2-fc71-4b29-9588-d5b16572cc77">N-acetylglutamate synthase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>N-acetylglutamate synthase deficiency: Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute hyperammonemia:</i> 100 to 250 mg/kg/day given in 2 to 4 divided doses (rounded to the nearest 100 mg); titrate to age-appropriate plasma ammonia levels and clinical symptoms. Concomitant adjunctive ammonia-lowering therapy recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic hyperammonemia: </i>10 to 100 mg/kg/day given in 2 to 4 divided doses (rounded to the nearest 100 mg); titrate to age-appropriate normal plasma ammonia levels. Consider concomitant adjunctive ammonia-lowering therapy and protein restriction based on plasma ammonia levels.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71d63a40-479a-4b5e-87c7-783143da5150">Propionic acidemia or methylmalonic acidemia, acute hyperammonemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Propionic acidemia or methylmalonic acidemia, </b>
<b>acute hyperammonemia: Oral:</b> 3.3 g/m<sup>2</sup>/day in 2 divided doses (12 hours apart); round dose up to the nearest 50 mg. Continue treatment until plasma ammonia level is &lt;50 micromole/L and for a maximum of 7 days; concomitant adjunctive ammonia-lowering therapy recommended.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992062"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption>
<b>Carglumic Acid Dose Adjustments for Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">eGFR (mL/minute/1.73 m<sup>2</sup>)</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 10 to 100 mg/kg/<i>
<b>day</b></i> in 2 to 4 divided doses</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 100 to 250 mg/kg/<i>
<b>day</b></i> in 2 to 4 divided doses</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 3.3 g/m<sup>2</sup>/<i>
<b>day</b></i> in 2 divided doses (12 hours apart)</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≥60</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;60</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 50 mg/kg/<b>day</b> divided in 2 to 4 doses (round to nearest 50 mg)</p></td>
<td align="center">
<p style="text-indent:0em;">50 to 125 mg/kg/<b>day</b> in 2 to 4 divided doses (round to nearest 50 mg)</p></td>
<td align="center">
<p style="text-indent:0em;">1.7 g/m<sup>2</sup>/<b>day</b> divided in 2 equal doses administered every 12 hours (round to nearest 50 mg)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;30</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 25 mg/kg/<b>day</b> divided in 2 to 4 doses (round to nearest 50 mg)</p></td>
<td align="center">
<p style="text-indent:0em;">15 to 60 mg/kg/<b>day</b> in 2 to 4 divided doses (round to nearest 50 mg)</p></td>
<td align="center">
<p style="text-indent:0em;">0.55 g/m<sup>2</sup>/<b>day</b> divided in 2 equal doses administered every 12 hours (round to nearest 50 mg)</p></td></tr></tbody></table></div>
<div class="block doha drugH1Div" id="F50989366"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dop drugH1Div" id="F10228990"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="17067" href="/d/html/17067.html" rel="external">see "Carglumic acid: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f3782e2-fc71-4b29-9588-d5b16572cc77">N-acetylglutamate synthase deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>N-acetylglutamate </b>
<b>synthase (NAGS) deficiency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute hyperammonemia, adjunct therapy</i>: Infants, Children, and Adolescents: Oral: 100 to 250 mg/kg/day in 2 or 4 divided doses; round to the nearest 100 mg (ie, ½ Carbaglu tablet); titrate to age-appropriate plasma ammonia concentrations and clinical condition considerations (including nutritional requirements, protein intake, growth parameters, etc); concomitant ammonia-lowering therapy recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic hyperammonemia</i>: Infants, Children, and Adolescents: Oral: Usual dose: 10 to 100 mg/kg/day in 2 or 4 divided doses; round to the nearest 100 mg (ie, ½ Carbaglu tablet); titrate to age-appropriate plasma ammonia concentrations and clinical condition considerations (including nutritional requirements, protein intake, growth parameters, etc). Rounding to the nearest 50 mg (ie, ¼ Carbaglu tablet) may be considered if a higher dose is not tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Carbaglu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Carbaglu.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffa79942-b6a3-4aa3-a3dc-5000f9cfaddd">Propionic acidemia or methylmalonic acidemia, acute hyperammonemia, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Propionic</b>
<b> acidemia (PA) or methylmalonic acidemia (MMA), acute hyperammonemia, adjunctive therapy:</b>
<b>Note: </b> Administer concomitantly with other ammonia lowering therapies (eg, IV dextrose, insulin, L-carnitine, protein restriction, dialysis).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≤15 kg: Oral: 150 mg/kg/day in divided doses every 12 hours. Round dose to the nearest 50 mg (ie, <sup>1</sup>/<sub>4</sub> Carbaglu tablet). Continue treatment until ammonia level is &lt;50 micromol/L and for a maximum of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Dose range of 100 to 250 mg/kg/day in divided doses every 6 to 12 hours has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-Carbaglu.2','lexi-content-ref-27653704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-Carbaglu.2','lexi-content-ref-27653704'])">Ref</a></span>); some have suggested use of a loading dose of 100 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-27653704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-27653704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 kg: Oral: 3.3 <b>grams</b>/<b>m<sup>2</sup></b>/day in divided doses every 12 hours. Round dose to the nearest 50 mg (ie, <sup>1</sup>/<sub>4</sub> Carbaglu tablet). Continue treatment until ammonia level is &lt;50 micromol/L and for a maximum of 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>). Doses in the literature range from 100 to 250 mg/kg/day in divided doses every 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-Carbaglu.2','lexi-content-ref-27653704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-Carbaglu.2','lexi-content-ref-27653704'])">Ref</a></span>); some have suggested use of a loading dose of 100 mg/kg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25205257','lexi-content-ref-27653704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25205257','lexi-content-ref-27653704'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090251"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Neonates, Infants, Children, and Adolescents: Oral:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Carglumic Acid Dose Adjustments for Altered Kidney Function</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">eGFR</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 10 to 100 mg/kg/day in 2 to 4 divided doses</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 100 to 250 mg/kg/day in 2 to 4 divided doses</p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 150 mg/kg/day in 2 divided doses (12 hours apart) for PA or MMA<sup>a</sup></p></th>
<th align="center">
<p style="text-indent:0em;">If the usual recommended dose is 3.3 g/m<sup>2</sup>/day in 2 divided doses (12 hours apart)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> PA = propionic acidemia; MMA = methylmalonic acidemia.</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Round dose to nearest 50 mg (<sup>1</sup>/<sub>4</sub> tablet).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">≥60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td>
<td align="center">
<p style="text-indent:0em;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">30 to &lt;60 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">5 to 50 mg/kg/day divided in 2 to 4 doses<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">50 to 125 mg/kg/day in 2 to 4 divided doses<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">75 mg/kg/day in 2 equal doses administered every 12 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">1.7 <b>g</b>/<b>m<sup>2</sup></b>/day divided in 2 equal doses administered every 12 hours<sup>b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="center">
<p style="text-indent:0em;">2 to 25 mg/kg/day divided in 2 to 4 doses<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">15 to 60 mg/kg/day in 2 to 4 divided doses<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">25 mg/kg/day in 2 equal doses administered every 12 hours<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;">0.55 <b>g</b>/<b>m<sup>2</sup></b>/day divided in 2 equal doses administered every 12 hours<sup>b</sup></p></td></tr></tbody></table></div>
<div class="block dohp drugH1Div" id="F51090252"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F10228969"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiomyopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Electrolyte disorder, hypoglycemia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, decreased appetite, dysgeusia, increased serum lipase, pancreatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Behavioral problems, drowsiness, encephalopathy, lethargy, sleep disorder, stupor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, hyperventilation, pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash, maculopapular rash, pruritus, pustular rash</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Mania</p></div>
<div class="block coi drugH1Div" id="F10228966"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to carglumic acid or any component of the formulation; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F10228967"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Plasma concentrations increased in patients with kidney impairment; dosage adjustment recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced physician: Acute symptomatic hyperammonemia is a life-threatening emergency; management of hyperammonemia due to N-acetylglutamate synthase deficiency should be done in coordination with those experienced in the management of metabolic disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nutritional management: Since hyperammonemia is the result of protein catabolism, complete protein restriction is recommended to be maintained for 24 to 48 hours and caloric supplementation should be maximized to reverse catabolism and nitrogen turnover.</p></div>
<div class="block foc drugH1Div" id="F10228998"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbaglu: 200 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg</p></div>
<div class="block geq drugH1Div" id="F10228962"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16322850"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Carbaglu Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $264.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet,Dispersible</b> (Carglumic Acid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $218.44 - $251.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871160"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Soluble, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbaglu: 200 mg</p></div>
<div class="block accres drugH1Div" id="F11285248"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Carbaglu is not available through pharmaceutical wholesalers or retail pharmacies, but only through direct shipping from the Accredo specialty pharmacy. Prescribers must contact Accredo Health Group at 888-454-8860 or refer to www.carbaglu.net to initiate patients on this product. For emergency (STAT) orders, call 877-900-9223.</p></div>
<div class="block adm drugH1Div" id="F10228993"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer immediately prior to meals or feedings. Disperse in water prior to administration; should not be mixed with any other foods or liquids other than water.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Do <b>not</b> swallow whole or crush. Disperse in water and administer immediately. Tablets do not dissolve completely, and some particles may remain; rinse container with water and administer rinse immediately; repeat as needed until no tablet pieces are left.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral syringe: After dispersion of tablets in water, draw up tablet and water mixture in oral syringe and administer immediately. After initial administration, pieces of tablet may remain in syringe; refill oral syringe with a minimum of 1 to 2 mL of water and administer immediately; repeat as needed until no pieces of tablet are left.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>NG tube/G-tube:</b> After dispersion of tablets in water, immediately administer through an NG tube or G-tube (tablets do not dissolve completely; some particles may remain). Flush immediately with 1 to 2 mL additional water to clear the tube; repeat as needed until no pieces of tablet are left in syringe or feeding tube.</p></div>
<div class="block admp drugH1Div" id="F52614225"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer immediately before meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Do not swallow whole or crush. Disperse in water and administer immediately. Tablets do not dissolve completely, and some particles may remain; rinse container with water and administer rinse immediately; repeat as needed until no tablet pieces are left. Carglumic acid tablets should not be mixed with any other foods or liquids other than water.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral syringe: After dispersion of tablets in water, draw up mixture into an oral syringe and administer immediately. After initial administration, pieces of tablet may remain in syringe; refill oral syringe with a minimum of 1 to 2 mL of water and administer immediately; repeat as needed until no pieces of tablet are left.</p>
<p style="text-indent:-2em;margin-left:2em;">NG or gastrostomy tube: After dispersion of tablets in water, draw up mixture in a catheter-tip syringe and immediately administer through an NG or gastrostomy tube. After initial administration, pieces of tablet may remain in syringe or tube; flush immediately with 1 to 2 mL additional water to clear the tube; repeat as needed until no pieces of tablet are left in syringe or tube.</p></div>
<div class="block use drugH1Div" id="F10109474"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, N-acetylglutamate synthase deficiency:</b> Adjunctive treatment of acute hyperammonemia and maintenance therapy of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase in adult and pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperammonemia, </b>
<b>propionic acidemia or methylmalonic acidemia</b>
<b>: </b>Adjunctive treatment of acute hyperammonemia due to propionic acidemia or methylmalonic acidemia in adult and pediatric patients.</p></div>
<div class="block cyt drugH1Div" id="F13298977"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F11304539"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F10228964"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Untreated maternal N-acetylglutamate synthase deficiency can trigger a hyperammonemic crisis leading to neurological impairment, coma, and possibly death. Information specific to the use of carglumic acid in pregnancy has not been located (Wilcox 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to carglumic acid is ongoing. Health care providers are encouraged to enroll patients exposed to carglumic acid during pregnancy in the pregnancy pharmacovigilance program (1-888-575-8344).</p></div>
<div class="block brc drugH1Div" id="F20613464"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if carglumic acid is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F10228996"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma ammonia concentrations; monitor for physical signs/symptoms of hyperammonemia (eg, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment).</p></div>
<div class="block pha drugH1Div" id="F10228978"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">N-acetylglutamate synthase (NAGS) is a mitochondrial enzyme which produces N-acetylglutamate (NAG). NAG is a required allosteric activator of the hepatic mitochondrial enzyme, carbamoyl phosphate synthetase 1, which converts ammonia into urea in the first step of the urea cycle. In NAGS-deficient patients, carglumic acid serves as a replacement for NAG.</p></div>
<div class="block phk drugH1Div" id="F10228980"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via intestinal flora to carbon dioxide.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 25 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 3 hours (range: 2 to 4 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (≤60% as unchanged drug); urine (9% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F56139435"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney function impairment:</b> The geometric mean ratio (90% CI) of AUC<sub>0-t</sub> in subjects with eGFR 60 to &lt;90, eGFR 30 to &lt;60, and eGFR ≤30 were approximately 1.3 (1.01, 1.68), 2 (1.65, 2.54), and 4.6 (3.36, 6.34), respectively, compared to subjects with normal kidney function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390246"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Carglumic acid waymade | Wayglumic</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ucedane</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Ucedane | Vizmato</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Carglumic acid waymade | Carglumsaeure waymade | Ucedane</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido carglumico waymade | Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Carglumic acid waymade | Ucedane</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acido carglumico waymade | Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Ucedane</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu | Kargluminsyra Waymade | Ucedane</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Perluga | Ucedane</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Carbaglu</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25205257">
<a name="25205257"></a>Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. <i>Orphanet J Rare Dis</i>. 2014;9:130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carglumic-acid-drug-information/abstract-text/25205257/pubmed" id="25205257" target="_blank">25205257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbaglu.1">
<a name="Carbaglu.1"></a>Carbaglu (carglumic acid) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbaglu.2">
<a name="Carbaglu.2"></a>Carbaglu (carglumic acid) [product monograph]. Milton, Ontario, Canada: Recordati Rare Diseases Canada Inc; November 2020.</div>
</li>
<li>
<div class="reference">
                  Carglumic acid [prescribing information]. Deer Park, IL: Eton Pharmaceutical Inc; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27653704">
<a name="27653704"></a>Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. <i>Curr Opin Pediatr</i>. 2016;28(6):682-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carglumic-acid-drug-information/abstract-text/27653704/pubmed" id="27653704" target="_blank">27653704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30198059">
<a name="30198059"></a>Wilcox G. Impact of pregnancy on inborn errors of metabolism. <i>Rev Endocr Metab Disord</i>. 2018;19(1):13-33. doi:10.1007/s11154-018-9455-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carglumic-acid-drug-information/abstract-text/30198059/pubmed" id="30198059" target="_blank">30198059</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9040 Version 161.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
